Takeda Advances Pediatric ENTYVIO Study, Supporting Long-Term Growth Potential

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study.

Takeda (TAK) is running a Phase 3 study called “An Open-Label, Phase 3 Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy.” The aim is to see how children and teens process a subcutaneous form of vedolizumab after responding to the IV version, which matters because it could support a more convenient long term option in serious bowel disease.

The study is testing vedolizumab, Takeda’s gut targeted anti inflammatory drug sold as ENTYVIO and KYNTELES, delivered first by IV and then by injection under the skin. The goal is to keep disease under control with a simpler dosing method that can be used at home while tracking safety and immune reactions in a young population.

Children enter the study on IV infusions of vedolizumab at different dose levels based on body weight, with treatments at Day 1 and at Weeks 2 and 6. Those who show a clinical response then shift into a maintenance phase where they receive fixed dose subcutaneous injections on a regular schedule to maintain benefit.

The trial is interventional and non randomized, so all enrolled patients receive vedolizumab with no placebo group. It is open label, meaning doctors and families know the treatment being given, and the main purpose is treatment focused rather than testing against a control, which simplifies recruitment but limits direct comparison data.

The study began enrollment after first submission on 17 Oct 2023, marking the formal start of this pediatric expansion push. The latest update filed on 05 May 2026 shows the trial is still active and recruiting, an important sign for investors that Takeda continues to invest behind ENTYVIO’s lifecycle and broader label reach.

For investors, this update reinforces Takeda’s effort to defend and grow ENTYVIO’s franchise as competition in inflammatory bowel disease intensifies from biologics and newer oral drugs. A successful pediatric subcutaneous label could extend revenue duration, support pricing, and improve patient stickiness versus rivals such as AbbVie and other large GI players.

The market impact near term is modest since no efficacy results are reported yet, but steady progress and ongoing recruitment should support sentiment around TAK’s immunology pipeline and long term cash flows. As the study moves toward completion and data disclosure, positive safety and exposure findings in children could become a quiet but meaningful catalyst for valuation and help offset pressure from biosimilar risk later in the decade.

The trial remains ongoing and recently updated, and investors can find further details on the ClinicalTrials.gov portal under identifier NCT06100289.

To learn more about TAK’s potential, visit the Takeda Pharmaceutical Company drug pipeline page.